Compound Emulsion Injection for Nausea and Vomiting
Summary
The USPTO published patent application US20260097042A1 for a compound emulsion combining aprepitant and palonosetron hydrochloride for injection. The formulation claims improved stability and enhanced patient adherence in preventing and treating nausea and vomiting. The application was filed on May 30, 2025.
What changed
The USPTO published a patent application for a compound emulsion formulation containing aprepitant and palonosetron hydrochloride for injection use. The invention addresses nausea and vomiting treatment with improved physical stability compared to existing formulations.
Pharmaceutical companies developing antiemetic products should review this application for potential freedom-to-operate implications. The published application provides public notice of the claimed invention, allowing competitors to assess their patent positions and design-around options. No regulatory compliance obligations are created by this publication.
What to do next
- Monitor for patent issuance
Archived snapshot
Apr 13, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOUND EMULSION, PREPARATION METHOD THEREFOR, AND USE THEREOF
Application US20260097042A1 Kind: A1 Apr 09, 2026
Inventors
Weiwei Zou, Donghai Wang, Zhichao Zhou, Qingmin Yang, Minghui Zhang
Abstract
The present disclosure provides a compound emulsion for injection of aprepitant and palonosetron hydrochloride. The compound emulsion has good stability and is more convenient and effective in preventing and treating nausea and vomiting, which improves patient medication adherence.
CPC Classifications
A61K 31/5377 A61K 9/0019 A61K 9/107 A61K 31/473 A61K 47/02 A61K 47/10 A61K 47/12 A61K 47/183 A61K 47/22 A61K 47/24 A61K 47/26 A61K 47/44 A61P 1/08
Filing Date
2025-05-30
Application No.
19223047
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.